ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Cohen Discusses the Challenges of Treating Medullary Thyroid Cancer

Ezra Cohen, MD
Published: Thursday, Oct 30, 2014



Ezra Cohen, MD, professor of medicine, UC San Diego Moores Cancer Center, discusses the challenges of treating patients with medullary thyroid cancer (MTC).

Cohen says there is a clear cohort of patients with MTC who have relatively indolent disease that doesn’t progress rapidly and therefore does not require treatment. However, for patients with progressive disease, physicians need to discuss treatment options and potential side effects, Cohen says. Additionally, it is important for all patients to undergo germline testing before treatment, since MTC can develop as a result of a hereditary syndrome Cohen says.

Once a therapy has been decided and started, physicians must follow the disease and manage the patients’ side effects. Unfortunately, all patients will end up progressing on their treatment. The biggest challenge in MTC, Cohen says, is that there is no third-line option following cabozantinib and vandetanib.

<<< View more from the 2014 ATA Annual Meeting



Ezra Cohen, MD, professor of medicine, UC San Diego Moores Cancer Center, discusses the challenges of treating patients with medullary thyroid cancer (MTC).

Cohen says there is a clear cohort of patients with MTC who have relatively indolent disease that doesn’t progress rapidly and therefore does not require treatment. However, for patients with progressive disease, physicians need to discuss treatment options and potential side effects, Cohen says. Additionally, it is important for all patients to undergo germline testing before treatment, since MTC can develop as a result of a hereditary syndrome Cohen says.

Once a therapy has been decided and started, physicians must follow the disease and manage the patients’ side effects. Unfortunately, all patients will end up progressing on their treatment. The biggest challenge in MTC, Cohen says, is that there is no third-line option following cabozantinib and vandetanib.

<<< View more from the 2014 ATA Annual Meeting


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x